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standing the pathogenesis of aHUS have led to a revised 
classification of the syndrome. Normal plasma levels of CFH 
and CFI do not preclude the presence of a mutation in these 
genes. Further, genotype-phenotype correlations of aHUS 
have clinical significance in predicting renal recovery and 
transplant outcome. Therefore, it is important to make a 
comprehensive analysis and perform genetic screening of 
the complement system in patients with aHUS to allow a 
more precise approach, especially before transplantation. 
This may also provide opportunities for more specific treat-
ments in the near future, as complement inhibition could 
represent a therapeutic target in these patients who have a 
considerably poor prognosis in terms of both mortality and 
progression to end-stage renal disease and a great risk of 
disease recurrence after transplantation. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Thrombotic microangiopathy (TMA) was first de-
scribed by Symmers  [81] in 1952. It has been defined as a 
histopathological entity of several disorders including 
the 2 main syndromes, the hemolytic uremic syndrome 
(HUS) and thrombotic thrombocytopenic purpura 
(TTP), and a related syndrome that occurs during preg-
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 Abstract 
 Atypical hemolytic uremic syndrome (aHUS) is a rare disease 
of microangiopathic hemolytic anemia, thrombocytopenia, 
and predominant renal impairment. It is characterized by 
the absence of Shiga toxin-producing bacteria as a trigger-
ing factor. During the last decade, aHUS has been demon-
strated to be a disorder of the complement alternative path-
way dysregulation, as there is a growing list of mutations and 
polymorphisms in the genes encoding the complement reg-
ulatory proteins that alone or in combination may lead to 
aHUS. Approximately 60% of aHUS patients have so-called 
‘loss-of-function’ mutations in the genes encoding the com-
plement regulatory proteins, which normally protect host 
cells from complement activation: complement factor H 
(CFH), factor I (CFI) and membrane cofactor protein (MCP or 
CD46), or have ‘gain-of-function’ mutations in the genes en-
coding the complement factor B or C3. In addition, approxi-
mately 10% of aHUS patients have a functional CFH deficien-
cy due to anti-CFH antibodies. Recent advances in under-
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nancy, i.e. the hemolysis, elevated liver enzyme, low plate-
let (HELLP) syndrome. TMA is characterized by the 
presence of fibrin and/or platelet thrombi in the micro-
circulation of various organs ( fig. 1 ). The pathophysiol-
ogy of TMA involves an initial endothelial cell injury in-
duced by various factors and followed by occlusions of 
small arterioles and capillaries by platelet plugs and/or 
fibrin thrombi. The common clinical features are micro-
angiopathic hemolytic anemia, thrombocytopenia and 
variable organ damage. Following the initial description 
of TTP by Moschcowitz  [82] . in 1924 and HUS by Gasser 
and co-workers  [83] in 1955, these 2 main syndromes of 
TMA had for a long time been distinguished considering 
only clinical aspects: HUS characterized by predominant 
renal involvement, i.e. acute renal failure, and TTP, of 
which predominant neurological involvement is a fea-
ture. However, the clinical presentation of these disorders 
can overlap and many factors can trigger HUS such as 
Shiga toxin (Stx)-producing enterobacteria, especially 
enterohemorrhagic  Escherichia coli  serotype 0157:H7 
(VTEC/STEC), or in some tropical regions  Shigella dys-
enteriae  type 1, which is  the most frequent form of HUS, 
with predominant occurrence in children called typical 
or postdiarrheal (D+) HUS  [1] , but also by pneumococcal 
(via neuraminidase of  Streptococcus pneumoniae  and T 
antigen exposure) and human immunodeficiency virus 
infections, metastatic cancers, organ and stem cell trans-
plantation, autoimmune diseases or drugs and it even oc-
curs without any identifiable trigger  [2] .
 Over the past decade, clinical and basic research has 
improved our understanding of the pathogenesis of TMA 
and helped to distinguish HUS from TTP. There have been 
2 major breakthroughs. The first was the identification 
that ADAMTS13 (a disintegrin-like and metalloprotease 
with thrombospondin type 1 repeats) deficiency is more 
likely to present with the insidious or fluctuating neuro-
logical signs of adult idiopathic TTP  [3–6] . But even severe 
ADAMTS13 deficiency does not account for all cases of 
idiopathic TTP  [7] . The second was the finding that abnor-
mal control of the alternative complement pathway is a 
risk factor for atypical HUS (aHUS)  [8, 9] . These results 
led to the recent proposal to use the terms of ‘ADAMTS13-
deficiency-related TMA’ and ‘complement-dysregulation-
related TMA’ rather than the terms TTP and HUS  [10] .
 In 2006, the European Paediatric Research Study 
group for HUS  [11] published a revised classification of 
HUS, TTP and related disorders, based on the contempo-
rary understanding of causation which can also be ad-
opted for adult patients and is still accurate (summarized 
in  table 1 ). In brief, patients can be classified as follows: 
Table 1. Classification [modified from 11]
Etiology advanced
1 Infection induced
a Stx-producing bacteria; enterohemorrhagic
E. coli, S. dysenteriae type 1, Citrobacter
b S. pneumoniae, neuraminidase, and T antigen exposure
c Other infectious agents
2 Disorders of complement regulation
a Genetic disorders of complement regulation
b Acquired disorders of complement regulation,
for example anti-CFH antibodies
3 Von Willebrand proteinase, ADAMTS13 deficiency
a Genetic disorders of ADAMTS13
b Acquired von Willebrand proteinase deficiency:
autoimmune, drug induced
4 Defective cobalamine metabolism
5 Drug induced (quinine)
Clinical associations: etiology unknown 
1 Human immunodeficiency virus
2 Malignancy, cancer chemotherapy and ionizing radiation
3 Calcineurin inhibitors and transplantation
4 Pregnancy, HELLP syndrome and oral contraceptive pill
5 SLE and antiphospholipid antibody syndrome
6 Glomerulopathy
7 Familial, not included in part 1
8 Unclassified
SLE = Systemic lupus erythematosus.
 Fig. 1. Example of renal biopsy findings in TMA showing fibrin 
thrombi in the glomeruli (labeled with  * ). 
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in the upper part, the cause is well established and in the 
lower part, disease or drug associations may be described 
but causation is not proven. The revised classification is 
in line with the idea that HUS can be caused by either, or 
both, an external environmental trigger and/or an intrin-
sic inherited risk factor and that in an individual patient 
the disease may have several etiologies. For example, a 
patient with complement factor H (CFH) gene mutation 
might present with an episode of HUS precipitated by in-
fection, perhaps even classical enterohemorrhagic  E. coli 
 infection.
 The aim of this review is to summarize the evident 
understanding of the pathophysiology of aHUS, the as-
sociation with complement dysregulation, to discuss 
treatment guidelines and, last but not least, to work out 
the future treatment options.
 The Complement System and Its Regulation 
 The complement system is an essential component of 
innate immunity with crucial roles in killing microor-
ganisms, apoptotic cell clearance, bridging of innate and 
adaptive immunity and production of anaphylatoxins. 
Complement is activated by 3 pathways: the classical 
pathway, the lectin pathway and the alternative pathway 
 [12] . These 3 pathways converge at the point of cleavage 
of C3 and have a common effector phase, initiating in-
flammation and microbial defense: (A) deposition of C3b 
molecules on the surface of microbes (opsonization), (B) 
formation of the terminal complex C5b–9 (the membrane 
attack complex, MAC), which results in lysis of microbes 
and (C) release of anaphylactic products such as C3a and 
C5a ( fig. 2 a). The alternative complement pathway is ini-
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 Fig. 2. Complement activation and control.  a Activation of the 
complement system proceeds by 3 pathways: the classical, the lec-
tin and the alternative pathway. Activation sets in motion a cas-
cade by which inactive zymogens convert to active proteins and 
the generation of the C3 convertase of the classical/lectin and the 
alternative pathway (C3bBb) as the critical step in complement 
activation. All 3 pathways converge at the point of cleavage of C3 
and have a common effector phase, initiating inflammation and 
microbial defense: (A) deposition of C3b molecules on the surface 
of microbes (opsonization), (B) formation of the terminal com-
plex C5b–9 (MAC), which results in lysis of microbes or (C) re-
leasing of anaphylactic products such as C5a (chemotaxis).  b Co-
valent binding of C3b on foreign surfaces such as microbes leads 
to binding of CFB, which is then cleaved by factor D to form the 
C3 convertase of the alternative pathway C3bBb, providing expo-
nential cleavage of C3b (the amplification phase of alternative 
complement pathway), and formation of the C5 convertase and of 
the MAC (the effector phase). Protection of host cells from forma-
tion of C3bBb on their surface is provided by soluble and mem-
brane-associated complement regulatory proteins such as CFH, 
CFI and MCP, respectively. Dysfunction of regulatory proteins by 
so-called ‘loss-of-function’ gene mutations (labeled with  † ) or an-
tibodies against CFH and gain-of-function mutations in the genes 
encoding CFB and C3 (labeled with  * ) lead to uncontrolled activa-
tion of the alternative complement pathway (described in detail in 
the text). 
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tiated by the autoactivation of C3, the formation of a C3 
convertase, followed by the generation of C3b. The C3b 
formed binds indiscriminately to surfaces as microbes 
and host cells. Covalent binding of C3b to pathogens 
leads to formation of further C3 convertases, providing 
the exponential cleavage of C3b (the amplification phase 
of complement activation) leading to MAC formation.
 The uncontrolled activated complement system has 
devastating effects; therefore, host cells are protected 
from damage ‘to self ’ and consumption of components of 
the complement system by soluble and membrane-asso-
ciated regulatory proteins, which keep the system in track 
and provide local protection of host cells. This local con-
trol system ensures that activation is mainly targeted to 
quickly remove invading pathogens. The importance of 
these regulators is demonstrated by the fact that there are 
almost as many regulatory proteins as there are proteins 
in the complement activation cascade  [12] . The comple-
ment regulators have 2 main mechanism of action: decay 
acceleration activity (i.e. decay of the C3 convertase) and 
cofactor activity. CFH is a fluid-phase regulator that has 
cofactor activity for the cleavage of C3b by complement 
factor I (CFI), and, in addition, has decay acceleration ac-
tivity. CFH is a most important complement regulator. 
For its cleaving function, the fluid-phase serine protease 
CFI is dependent on cofactor activity. The membrane co-
factor protein (MCP or CD46) is a resident transmem-
brane protein expressed on almost every human cell ex-
cept erythrocytes. It is the second important cofactor for 
CFI for the cleavage of C3b and further promotes the de-
cay of the C3 convertase. The activation and regulation 
of the alternative pathway is shown in  figure 2 b.
 The impairment of the alternative pathway regulation 
leads to excessive liberation of different cleavage frag-
ments such as the anaphylatoxins C3a and C5a and the 
unrestricted formation of the MAC. All components me-
diate different signaling pathways  [13–16] , leading to in-
flammation and platelet activation, and especially the 
MAC is capable of participating in the microangiopathic 
lesions of the kidney as shown in animal models  [17–
19] .
 aHUS Associated with Gene Mutations in 
Complement Regulatory Proteins 
 Nondiarrheal HUS or aHUS is a clinically defined 
form of TMA characterized by predominantly renal in-
volvement, absence of Stx-producing bacteria as a trig-
gering factor and is associated with relapses and a poor 
outcome. Overall, aHUS is less common than Stx-associ-
ated HUS and accounts for only 5–10% of all cases of HUS 
 [9] .
 In 1981, Thompson and Winterborn  [20]  described 
the correlation of hypocomplementemia (i.e. reduced C3 
level) and the involvement of the alternative complement 
pathway in the pathogenesis of aHUS. In 1998, Warwick-
er et al.  [21]  reported a link between aHUS and a region 
of chromosome 1q32 by genetic studies of 3 large families. 
This region contains a group of genes that have a central 
role in the regulation of complement activation: the regu-
lators of complement activation (RCA) gene cluster. The 
innovative report of Warwicker et al.  [21] and the subse-
quent descriptions of different mutations, all within genes 
encoding regulatory proteins of the alternative pathway, 
provided substantial evidence that uncontrolled activa-
tion of complement plays a central role in the pathogen-
esis of aHUS  [8,  22–25] .
 Nowadays, aHUS can be described as a disease of al-
ternative pathway dysregulation. There is a growing list 
of mutations and polymorphisms in genes encoding 
complement regulatory proteins that alone or in combi-
nation may lead to aHUS. The most frequently reported 
mutations are in the gene encoding CFH and account for 
50–60% of cases associated with documented genetic ab-
normalities. Mutations in the genes encoding MCP and 
CFI are observed in approximately 20 and 10–15% of the 
overall disease-associated mutations, respectively (data 
from registries  [22, 24, 26] and individual centers). Im-
portantly, mutations in the genes encoding regulatory 
proteins are so called ‘loss-of-function’ mutations. There 
are now reports emerging that ‘gain-of-function’ muta-
tions in the genes encoding factor B (CFB) or C3 have also 
been detected in a few patients with aHUS  [27, 28] . These 
data expand our understanding of the critical role of the 
alternative pathway in the pathogenesis of aHUS. The in-
cidence of mutations in proteins of the alternative path-
way in patients with aHUS is illustrated in  table 2 .
 Complement Factor H 
 Mainly synthesized by the liver, CFH is a single poly-
peptide chain glycoprotein of 150 kDa composed of 20 
repetitive units of 60 amino acids, named short consen-
sus repeats (SCR), arranged in a continuous fashion  [29] . 
The CFH molecule includes different interaction sites for 
C3b and polyanions ( fig. 3 ). The C3b binding site in 
SCR1–4 is the only site essential for the CFI cofactor ac-
tivity of CFH. Similarly, the C3b/polyanions-binding site 
located within SCR19–20 is the most important site for 
preventing alternative complement pathway activation 
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on host cells, showing distinct functional domains at the 
N- and C-terminal site of the CFH molecule, respectively 
 [30] . Extrahepatic synthesis of CFH also occurs in a wide 
variety of cell types, such as glomerular mesangial cells, 
retinal pigment epithelial cells, peripheral blood lympho-
cytes, myoblasts, fibroblasts, umbilical vein endothelial 
cells, or neurons. The extrahepatic synthesis of CFH is 
interpreted as a mechanism to increase the local concen-
tration of CFH for the protection of host cells from com-
plement activation in sites of infection or inflammation.
 In the human plasma, there are 6 proteins that are 
structurally related and cross-react immunochemically 
with CFH. Factor H-like protein FHL-1 is the product of 
alternative splicing of the gene-encoding CFH  [31] and in 
addition there are 5 related proteins (CFHR1, CFHR2, 
CFHR3, CFHR4, CFHR5), that are encoded by 5 different 
genes  [32] . These proteins are probably synthesized by the 
liver, but their concentrations in the plasma are much 
lower than that of CFH and their functional properties 
are not defined completely. The CFH gene is a member of 
the RCA gene cluster on chromosome 1q32  [33] . At pres-
ent, 100 distinct CFH gene mutations or polymorphisms 
have been reported in aHUS patients  [34] . All reported 
mutations were heterozygous, except in 15 patients (most-
ly from consanguineous families) with homozygous CFH 
deficiency  [35] and a few cases of compound heterozy-
gous mutations. The majority of mutations published up 
to now have been located within the C-terminal domain 
of the protein, particularly in SCR20 revealing a hot spot 
for mutations as shown in  figure 4 . Carriers of mutations 
in SCR19–20 express CFH molecules with a reduced abil-
ity to bind to surfaces, including polyanions of the endo-
thelial cell and, thus, have limited capacity to protect host 
surfaces from alternative pathway activation but present 
normal regulatory (cofactor) activity in the fluid phase, 
i.e. in the plasma  [36] . This limited complement regula-
tory capacity could lead to specific susceptibility to the 
development of aHUS as a situation of ‘autolesion’ caused 
by uncontrolled activation of complement in the kid-
neys.
 It is interesting to note that only a few reported CFH 
gene mutations have been associated with quantitative 
CFH deficiency as defined by an antigenic plasma level 
below half normal; however, the antigenic level was not 
determined in every case  [8] .
 In recent years, considerable evidence has been gener-
ated to support the hypothesis that both the membrano-
proliferative glomerulonephritis type II (MPGN2) and 
age-related macular degeneration (AMD) are further dis-
eases caused by dysregulation of the alternative comple-
ment pathway. Several reports illustrate a remarkable 
genotype-phenotype correlation in which distinct genet-
ic variations and mutations of CFH and related proteins 
predispose specifically to MPGN2, AMD or aHUS. In 
particular, the  CFH His402 variant in SCR7 of CFH has 
consistently been shown to be associated with increased 
risk to develop AMD in numerous studies  [37] . MPGN2 
is associated with CFH gene mutations or autoantibodies 
directed against CFH but is also associated with autoan-
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20NH2 COOH
C3b
Cofactor acvity/
Decay accelerang acvity
Hep C3b C3b
Cell surface regulaon
Hep
Sialic acid
Hep
 Fig. 3. Structure of CFH with the 20 SCR 
arranged in continuous fashion and its 
functional domains. CFH has 3 C3b-bind-
ing sites: SCR1–4, SCR12–14 and SCR19–
20, respectively. Similarly, a total of 3 sepa-
rate binding sites for heparin and sialic 
acid have been identified in SCR7, SCR13 
and SCR19–20, respectively. The critical 
sites for cofactor activity/decay accelerat-
ing activity and cell surface regulation at 
the N- and C-terminal sites, respectively, 
are indicated. 
Table 2. Incidence of mutations in proteins of alternative comple-
ment pathway in patients with aHUS
Gene Location Frequency
in aHUS, %
Ref. No.
CFH RCA gene Chr 1 10–30 8, 22–24, 26, 34
MCP RCA gene Chr 1 10–15 8, 22–24, 34, 41
CFI Chr 4 5–10 8, 22, 34, 42, 43
CFB Chr 6 0–3 27
C3 Chr 19 N/A 28
Chr = Chromosome; N/A = not available.
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tibodies directed against the C3 convertase of the alterna-
tive pathway called C3NeF. The coincidence of CFH de-
ficiencies with strong complement activators such as 
C3NeF may be critical in the development of MPGN2 in-
stead of aHUS. Interestingly, MPGN2 also associates 
with alleles of CFH and CFHR5 genes. A more extensive 
description of MPGN2 or AMD and the association with 
defective alternative pathway control have been given 
previously  [38] .
 MCP (CD46) 
 MCP is a widely expressed transmembrane glycopro-
tein that inhibits complement activation on host cells by 
serving as a membrane-bound cofactor for the plasma 
serine protease CFI to cleave C3b and C4b. The N-termi-
nal site of MCP consists of 4 SCR. This extracellular por-
tion of MCP is followed by a hydrophobic transmem-
brane domain and a cytoplasmatic anchor. Sites for C3b 
and C4b interactions have been mapped to SCR2, SCR3 
and SCR4  [39] . The MCP gene is located within the RCA 
gene cluster on chromosome 1q32 and therefore was con-
sidered to be a candidate gene for mutations in patients 
with aHUS  [40] . Richards et al.  [41]  identified for the first 
time functionally significant MCP gene mutations in 7 
patients (3 pedigrees) presenting a family history of aHUS 
with a recessive form of inheritance. Since then, 25 dis-
ease-associated mutations due to homozygous, heterozy-
gous or compound heterozygous forms of inheritance 
and 5 disease-associated polymorphisms have been iden-
tified  [34] . Most of the mutations were found in the 4 N-
terminal SCR domains with the exception of 1 mutation 
found in the transmembrane domain. To illustrate this, 
 figure 5 shows the location of the MCP gene mutations 
which have been identified in Italian and French cohorts 
of aHUS patients  [22, 24] . Over 80% of all reported muta-
tions caused a reduction in MCP surface expression, 
whereas as small proportion resulted in only a functional 
defect. Further, in the French cohort, 2 individuals were 
described for the first time without any surface expres-
sion of MCP. Serum C3 levels in patients with MCP gene 
mutations were normal or slightly lower than normal, 
leading to the hypothesis that local dysregulation of the 
complement system in the kidney by reduced cofactor ac-
tivity of mutant MCP predisposes to severe TMA in the 
renal vasculature.
 Complement Factor I 
 CFI is a 2-chain serine protease in which the light 
chain carries the catalytic domain, while the function of 
the heavy chain, containing 2 low-density lipoprotein re-
ceptor domains and a CD5 domain (also called FIMAC), 
is unclear. CFI is predominantly synthesized by the liver 
and downregulates the alternative pathway by cleaving 
C3b, but is efficient only in the presence of cofactor pro-
Asp1119Gly
Val1134Gly
Tyr1142Asp
Trp1157Arg
Cys1163Trp
c.3493+1G>A
c.3559delA
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20NH2 COOH
Ile32Del
Arg78Gly
Glu189X
Gln400Lys
His402Tyr
Cys431Ser
Cys536Arg
Cys630Trp
Cys673Tyr
c.2373_2374insA Val1007Cys
Tyr1021Phe
Cys1043Arg
Ser890Ile
His893Arg
Tyr899X
Cys915Ser
Gln924X
c.371-397del
Arg78Gly c.1494delA Ser714X
Val835Leu
Glu850Lys Gin1076Glu
Gin950His
Tyr951His
Thr956Met
Cys959Tyr 
Cys973Tyr
Trp978Cys
Glu1172X
Arg1182Ser
Trp1183Arg
Trp1183Leu
Thr1184Arg
Leu1189Arg
Leu1189Phe
Ser1191Leu
Ser1191Trp
Gly1194Asp
Val1197Ala
Glu1198Ala
Phe1199Ser
Arg1210Cys
Arg1215Gly
Arg1215Gln
Thr1216del
Pro1226Ser
[c.3674A>T;
c.3675_3699del]
c.3695_3698del
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 Fig. 4. The majority of the gene mutations 
associated with aHUS cluster in the C-ter-
minal region of CFH. The structure of 
CFH is shown with the 20 SCR and the 
most representative mutations reported in 
the literature are indicated. The majority 
of mutations in the CFH gene are missense 
mutations, resulting in a single amino acid 
exchange.  
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teins (i.e. CFH and MCP). The CFI gene is located outside 
the RCA gene cluster on chromosome 4q25  [8] .
 In 2004, Frémeaux-Bacchi et al.  [42]  reported for the 
first time the clinical courses of 3 aHUS patients present-
ing with mutations in the CFI gene. Today, the database 
contains a total of 16 disease-associated mutations in the 
CFI gene and the majority of these mutations are within 
the catalytic domain of the light chain  [34] . Further, most 
CFI gene mutations induce a lack of protein synthesis, 
and only few mutations have been associated with a func-
tional deficiency. CFI gene mutations appear to be a less 
common cause of aHUS (between 5 and 10% of all aHUS 
patients) than are CFH and MCP gene mutations  [22, 24, 
42, 43] .
 Recent Identification of Gain-of-Function Mutations 
 Goicoechea de Jorge et al.  [27]  identified a subgroup of 
aHUS patients without mutations in the genes encoding 
complement regulatory proteins, showing persistent ac-
tivation of the alternative pathway with very low serum 
levels of C3 and normal or elevated serum levels of C4. 
They found within that subgroup 2 families with hetero-
zygous mutations in the gene encoding CFB. CFB is a 
zymogen that carries the catalytic site of the alternative 
pathway convertase C3bBb. Upon interaction with C3b, 
CFB is cleaved by complement factor D into 2 fragments, 
Ba and Bb. Ba is released and Bb remains bound to C3b, 
forming the convertase C3bBb, an active serine protease 
that cleaves additional C3 into C3b as shown in  figure 2 b. 
Functional analysis demonstrated that aHUS-associated 
CFB gene mutations are gain-of-function mutations that 
result in enhanced formation of C3bBb convertase or in-
creased resistance to inactivation by complement regula-
tory proteins. Taken together, these data highlight that 
alternative pathway overactivation by gain-of-function 
mutations may lead to the pathogenesis of aHUS, al-
though mutations in the CFB gene are rare, accounting 
for 0–3% of disease-associated mutations  [34] .
 Further, the group of Frémeaux-Bacchi et al.  [28] de-
scribed in 2 independent cohorts (Newcastle and Paris) 9 
novel distinct mutations of complement C3 in 14 patients 
with aHUS with persistently low serum C3 levels. Func-
tional assays were performed with 7 expressed C3 mu-
tants to assess the interaction of the secreted C3 mutants 
with MCP and demonstrated that 5 of these C3 mutants 
had decreased MCP binding and cofactor activity. Thus, 
the reduced interaction of these 5 of the 7 secreted C3 
mutants with MPC is likely to induce gain of function 
relative to alternative pathway activation  [28] .
 Combined Mutations in aHUS, Other Susceptibility 
Factors and Genetic Variability 
 Mutations in genes encoding complement proteins are 
identified in at least 50% of cases with familial or sporad-
ic aHUS reported in the literature. It is important to note 
that about 10% of patients have combined mutations, es-
pecially of CFI gene mutations with either CFH or MCP 
gene mutations  [22] . Penetrance of aHUS associated with 
mutations in genes encoding regulatory proteins or com-
plement activators has been reported to be approximately 
50% in all series, suggesting that the inheritance of a sin-
gle mutation may be insufficient to cause aHUS by itself.
 To identify additional aHUS susceptibility factors, the 
regulator genes have been analyzed further in genetic
association studies  [44, 45] . These and subsequent rep-
lication studies  [27, 46–48] demonstrated 2 relatively
frequent CFH and MCP gene alleles ( CFH-H3  and
 MCPggaac  haplotypes) that were significantly more fre-
quent in aHUS patients (either with or without CFH, MCP, 
CFI, or CFB gene mutations) than in controls. Moreover, 
it could be shown that family members with complement 
regulatory or CFB gene mutations developing aHUS had 
inherited the allele carrying the genetic mutation from one 
parent and the allele carrying the disease-associated CFH 
and/or MCP gene haplotype from the other parent. Most 
1
2
3
4 F208C
c.843-844delAC
c.858-872del15bp
IVS2-2A>G
C65R
c.236-241delA
IVS1-1G>C 
R25X
C1Y and R25X
IVS2+2(Ho)-1G>C
R25X
Y155D
Y155D and D151N
Y214X
B
C
A304V
French cohort Italian cohort
CO
O
H
N
H
2
TM
 Fig. 5. Summary of the MCP gene mutations located within the 
SCR1–4 domains and 1 mutation within the transmembrane do-
main form the Italian (right) and the French (left) cohort. TM = 
Transmembrane domain. 
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interestingly, the healthy CFH, MCP, CFI or CFB gene mu-
tation carriers in these families did not inherit the aHUS-
associated CFH and/or MCP gene polymorphism. Al-
though additional studies are needed to fully characterize 
the role of these CFH and MCP gene haplotypes, the as-
sociation of  CFH-H3  and MCPggaac  haplotypes with 
aHUS is important because it indicates that polymorphism 
of the genes encoding CFH and MCP may predispose to 
aHUS in the absence of other mutations and that even in 
carriers of mutations, additional regulator gene variants 
may be needed for the development of the disease (‘mul-
tiple-hit hypothesis’)  [38] . In practice, the implication of 
incomplete penetrance of the disease within families is 
that it is not possible for an individual family member pre-
senting with a mutation and/or risk polymorphism to fore-
cast the risk of the occurrence of aHUS. Even so, environ-
mental triggers or precipitating events also appear to be a 
prerequisite for the development of the disease. In sum-
mary, mutations in genes encoding complement regula-
tory proteins or complement activators predispose to 
aHUS rather than they are causative per se.
 Acquired Dysregulation of the Alternative 
Complement Pathway 
 In addition to gene mutations encoding complement 
regulatory proteins, CFH autoantibodies leading to an 
acquired functional CFH deficiency have been reported 
in aHUS patients, mostly in children  [49–51] . The bind-
ing epitopes of the autoantibodies were localized to the 
C-terminal recognition region of CFH. This overlap with 
the majority of mutations within the C-terminal domain 
of the protein, particularly in SCR20, suggests similar 
functional consequences for the CFH autoantibodies and 
for the genetic mutations. Interestingly, individuals pre-
senting with CFH autoantibodies are, with very few ex-
ceptions, homozygous for the deletion of the CFHR1 and 
CFHR3 genes. Whether the deletion of these genes and 
the presence of CFH autoantibodies are independent risk 
factors for aHUS remains unclear.
 Clinical Characteristics of aHUS Associated with 
Alternative Complement Dysregulation 
 In the last decade, data from registries  [22, 24, 26] and 
individual centers have made it possisble to study the 
clinical characteristics of aHUS in accordance with the 
identified risk factors.
 Triggering Events 
 It is worth noting that there is a high frequency of in-
fectious triggering events in patients with aHUS, espe-
cially upper respiratory tract infections, fever and diar-
rhea  [22, 24] . Diarrhea preceded aHUS in nearly 30% of 
patients from all subgroups, including Stx-associated 
bloody diarrhea in one child with an MCP gene mutation 
 [24] . Harboring a MCP gene mutation could probably be 
a risk factor for a severe outcome of Stx-associated HUS, 
as a 4-year-old patient with an MCP gene mutation died 
from multivisceral involvement after Stx-associated HUS 
 [52] . Another observation of an adult patient with a CFH 
gene mutation and severe diarrhea-positive HUS has also 
been reported  [53] .
 Age at Onset of the Disease 
 Stx-associated HUS is the most common cause of acute 
renal failure in childhood  [1] ; on the other hand, aHUS 
may manifest at all ages but is more frequent in adoles-
cent and adult patients  [54] . Early age at onset in children 
appears to be characteristic of aHUS associated with CFH 
and CFI gene defects, while aHUS associated with MCP 
gene mutations is not seen before the age of 1 year  [22, 
24] .
 Familial aHUS 
 The incidence of familial aHUS ranged from less than 
10% in the aHUS registry of the German-speaking coun-
tries  [26] to 25% in the French  [24] and 37% in the Italian 
aHUS registry  [22] , respectively, and the gender ratio was 
equilibrated. The frequency of familial aHUS is similar 
in the groups with CFH, MCP and CFI gene mutations 
and in the group with no mutation. Most frequently in 
familial aHUS, the disease occurs in siblings but may also 
be present in different generations. The absence of a fam-
ily history of aHUS does not exclude the possibility of a 
genetic transmission of the disease.
 Clinical Course and Outcome 
 Extrarenal involvement during HUS flares in aHUS 
patients with alternative complement dysregulation is 
very rare. Involvement of the central nervous system is 
found in around 30% of children with typical HUS and 
in these patients, it is the most common cause of mortal-
ity  [55] . Concerning data from registries of aHUS pa-
tients  [22, 24, 26] the clinical characteristics are best de-
scribed in the French pediatric cohort (46 children). Few-
er than 10% of these patients had extrarenal involvement 
(4 patients, including 1 with CFH mutation, and 3 with 
unexplained HUS had cerebrovascular events, 1 of these 
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patients had pulmonary involvement, too)  [24] . More-
over, information obtained from literature research is 
poor. We found a single case report of a male child with 
congenital homozygote CFH deficiency who had an ocu-
lar hemorrhagic and ischemic involvement in one eye af-
ter 3 years of uneventful hemodialysis  [56] . Ocular TMA 
has never been reported in patients with CFH mutations 
before but has recently been reported in a few pediatric 
patients with typical HUS  [57] . Furthermore, in a clini-
copathological study of 24 children with HUS (12 of them 
with typical presentation characterized by a diarrheal 
prodrome), involvement of the gut (severe colitis) has 
been reported in a few children leading to death during 
the acute phase of the disease as well as pancreatic islet 
cell necrosis leading to diabetes  [58] , but has never been 
reported in adult patients with aHUS associated with al-
ternative complement dysregulation.
 The overall prognosis of aHUS is poor with a high rate 
of mortality and recurrence. In the French padiatric co-
hort (46 children) and the Italian cohort (156 patients; 
about 30% adults) 9 and 10% of patients, respectively, 
died  [22, 24] . A relapsing course of the disease may occur 
whatever the genotype underlying the disease as well as 
in patients with no identified gene mutation  [22, 24, 26] . 
However, the number of relapses is significantly more 
important in the MCP gene-mutated and in mutation-
negative patients. Relapses with complete recovery are 
mainly characteristic of patients with MCP gene muta-
tions and some patients with no identified mutation. Poor 
clinical long-term outcome defined as end-stage renal 
disease (ESRD) is not only seen in patients with an iden-
tified gene mutation but also in mutation-negative pa-
tients in high frequency (up to 70% in the registry of Ger-
man-speaking countries  [26] ). aHUS associated with 
MCP gene mutations has the best prognosis of all geno-
typed cohorts. Renal function is generally preserved for 
years despite a relapsing course of the disease, although 
approximately 20–30% of patients will reach ESRD  [22, 
24] .
 Patients with CFH gene mutations tend to have the 
worst prognosis with early onset of the disease followed 
by a relapsing course, and 70% of cases progress to ESRD 
or die  [22, 24] . Among the French children, 60% of those 
with CFH gene mutation had either died or reached ESRD 
by 1 year after disease onset in comparison to 32% in the 
group with no identified gene mutation and 0% of the 
MCP gene-mutated children  [24] . Similar severe clinical 
outcome with progression to ESRD or death is seen in 
patients with CFI gene mutations; among the French and 
Italian cohorts 50 and 70%, respectively, reached ESRD 
 [22, 24] . The clinical course and outcome of patients with 
gain-of-function mutations (i.e. CFB or C3 gene muta-
tions) is not well documented in the literature.
 Investigation – A Diagnostic Algorithm 
 Figure 6 illustrates a diagnostic algorithm which is in-
tended to help physicians to distinguish between ‘atypi-
cal’ and more common forms of HUS based on consensus 
from expert opinion as evidence is lacking because of the 
rarity of these disorders. It offers an approach to the cur-
rent revised classification of HUS, TTP and related dis-
orders from the European Paediatric Research Study 
group for HUS  [11] , which helps us to identify the etiol-
ogy of specific diagnostic subgroups of HUS. It is built up 
to recognize those cases of HUS that have etiologies oth-
er than enterohemorrhagic  E. coli  or S. dysenteriae  type 
1 infections (= post-diarrheal (D+) HUS) that are called 
‘atypical’ (= aHUS) and mainly addresses the question: 
‘How should I investigate a new patient with aHUS?’ 
Whether invasive  S. pneumoniae  infection-induced HUS 
should be called ‘atypical’ or not is still a matter of debate. 
For a comprehensible illustration in the diagnostic algo-
rithm, this form of HUS is listed separately. Therapeutic 
strategies in patients with aHUS are discussed below.
 Following the recognition of HUS, cases should be al-
located to 1 of the 3 clinically recognizable patterns of 
disease presentation indicated in  figure 6 . 
 (A) Children older than 6 months presenting with di-
arrhea or bloody diarrhea require investigation to deter-
mine the cause of the gastrointestinal infection, includ-
ing stool cultures, enhancement and selection techniques, 
gene probes for Stx subtypes and serotyping of the identi-
fied enterohemorrhagic enterobacteria, using local mi-
crobiological services.
 (B) Patients with suspected invasive pneumococcal in-
fection first of all need bacteriological confirmation by 
blood cultures. T antigen exposure on red blood cells 
strongly supports the diagnosis.
 (C) All other cases of HUS can be regarded as aHUS 
and require full investigation (see section ‘Investiga-
tion – The Clinical Utility of Genetic Screening’ below).
 Notes on the Algorithm ( fig. 6 ) 
 (1) The cutoff point of 6 months is to some extent ar-
bitrary, but exposure to Stx-producing organisms, i.e. en-
terohemorrhagic  E. coli or  S. dysenteriae  type 1, is less 
likely before the age of 6 months. Between 1 and 5 years 
of age, the incidence of Stx (D+) HUS exceeds all other 
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Invasive Streptococcus 
pneumoniae infection 
(pneumonia, meningitis, 
septicaemia, especially if there
Recognition of HUS 
No recent diarrhea 
or
followingis located infection such as 
empyema or subdural
collection) 
Recent diarrhea but one of the 
-   manifestation at all ages1
-   insidious onset2
-   relapse of HUS
-   previous unexplained
anemia or acute renal failure
-   HUS post-transplantation of
any organ3 
-   asynchronous family history 
of HUS4 
Full investigation for
alternative causes of HUS is 
required
Stool culture and investigation 
for Stx-producing
enterobacteria is
recommended routinely as 
unusual presentations occur5
Consider combined host and
environmental factors; i.e. 
more than one aetiology is 
possible 
See section “Investigation – 
the clinical utility of genetic 
screening”
Pneumococcus-induced HUS is 
likely to be the only cause 
A
and
or
and
B C
Age > 6 months 1 
a)   enterohemorrhagic 
       Escherichia coli endemic 
       region 
b)   Shigella dysenteriae type 1 
       endemic region 
(D+) HUS is likely to be the 
only cause 
Diarrhea or bloody diarrhea in 
the two weeks before
diagnosis of HUS 
 Fig. 6. Diagnostic algorithm: recognition of aHUS. Letters (A–C) and superscript numbers (1–5) refer to those 
used in the text.  
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causes  [1] . On the other hand, aHUS may manifest at all 
ages. Concerning children, HUS which presents before 6 
months of age or in adolescent patients is highly suspi-
cious for aHUS triggered by disorders of complement 
regulation.
 (2) (D+) HUS or HUS induced by pneumococcal infec-
tion is rapid in onset. Hemolytic anemia, thrombocyto-
penia and acute renal failure become apparent over a few 
days  [1] . HUS induced by complement dysregulation or 
ADAMTS13 disorders can also abruptly occur. However, 
an insidious onset over more than 1 week, fluctuating 
clinical signs and laboratory parameters increase the 
likelihood of a noninfective cause  [22, 24] .
 (3) HUS can follow transplantation of any organ  [59, 
60] . The role of drugs, especially calcineurin inhibitors, 
has been suspected but not proven  [61] . HUS after renal 
transplantation raises the question of a host risk factor, 
whether or not the original cause of the patient’s ESRD 
was known to be HUS.
 (4) In an outbreak of infection caused by Stx-producing 
enterobacteria, family members may develop HUS, either 
simultaneously (same source of infection) or a few weeks 
apart (secondary spread). These families do not require 
investigation beyond confirmation of the infection. By 
contrast, families with asynchronous HUS are very likely 
to have inherited risk factors and require full investigation 
(see also section ‘Clinical characteristics of aHUS associ-
ated with alternative complement dysregulation’).
 (5) Stx-producing enterobacteria infection can cause 
HUS without diarrhea  [1] . Also, urinary tract infection 
caused by Stx-producing enterobacteria is described in 
the literature  [62] . Therefore, screening for Stx-producing 
organisms has to be done routinely for all patients who 
are recognized as having HUS.
 Investigation – The Clinical Utility of Genetic 
Screening 
 As described above, gene mutations predispose to 
aHUS rather than they directly cause it. This means that 
for an individual with a gene mutation the risk of devel-
oping aHUS can only be estimated. However, as geno-
type-phenotype correlations can be seen in those indi-
viduals with gene mutations who have developed aHUS, 
it is clearly helpful to know by which complement muta-
tion an individual is affected. Further, unaffected family 
members with a known complement mutation should be 
monitored during periods of increased risk (such as preg-
nancy and infections).
 Considering the therapeutic implications, not only a 
comprehensive complement analysis in the plasma (i.e. 
complement C3, C4, CFH, CFI, and CFB antigenic levels), 
membrane expression of MCP in blood leukocytes and 
screening for anti-CFH antibodies in any individual with 
aHUS is mandatory, but also a genetic analysis of the 
genes encoding complement proteins.
 A consensus agreement from the European Working 
Party on the Genetics of HUS has recently described a 
screening protocol for the detection of mutations in aHUS 
 [63] . The National Institutes of Health-funded website 
GeneTests (http://www.genetest.org) provides informa-
tion on laboratories which offer genetic screening in 
aHUS.
 Concerning complement analysis, it is worth noting 
that if the C3 level is low, this indicates complement dys-
regulation but C3 levels may be normal in patients with 
complement dysregulation. Further CFH and CFI plasma 
concentrations may be normal in cases with mutations. 
Therefore, normal results of C3, CFH and CFI plasma 
concentrations  do not exclude a complement disorder 
 [34] . Investigation of ADAMTS13 activity is indicated 
routinely to distinguish between ‘ADAMTS13-deficien-
cy-related TMA’ and ‘complement-dysregulation-related 
TMA’.
 Therapeutic Strategies in Patients with aHUS 
 In practice, the complex laboratory investigations 
needed to confirm the etiology take several weeks and 
genotyping even longer. Therefore, although much prog-
ress in understanding the pathogenesis of the disease has 
been made in the last decade, initial treatment still has to 
be empirical. Up-to-date recommendations for clinical 
practice are summarized in  table 3 .
 Plasma Therapy 
 There are many reports on plasma therapy in aHUS, 
but there are no clinical controlled trials. Nevertheless, 
plasma-based therapies remain the first-line treatment, 
although evidence is lacking. The recently published 
guidelines from the European Paediatric Study Group for 
HUS  [64] argue for plasma exchange (PE), replacing it 
with fresh frozen plasma (FFP) or a standardized whole 
plasma product such as Octaplas  and recommend to 
start plasma therapy as early as possible, within 24 h of 
presentation, in parallel with conservative treatment (i.e. 
dialysis, transfusion, antihypertensive treatment, etc.). 
This is suggested on the basis that PE would remove mu-
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tant complement proteins (circulating plasma factors 
such as CFH, CFI, CFB and C3) responsible for the dis-
ease and autoantibodies to CFH or ADAMTS13, while 
restitution with FFP restores the functional proteins. In 
addition, PE prevents volume overload and cardiac fail-
ure when large amounts of FFP are infused. The Euro-
pean Paediatric Study Group for HUS justifies the ur-
gency and invasive nature of this approach with the fact 
that TMA of the kidney is a destructive process and that 
a first episode of the disease may rapidly lead to ESRD. 
The few patients with a complete quantitative deficiency 
of complement proteins such as CFH might do well sim-
ply with FFP infusions that provide the normal protein. 
However, the majority of patients have functional defi-
ciency of one or several complement proteins. Thus, PE 
could be necessary to withdraw mutant proteins as shown 
by a report of Davin et al. [65] of 2 twin sisters with func-
tional CFH deficiency secondary to heterozygous CFH 
gene mutation. In patients with MCP gene mutations, 
plasma therapy is not expected to have a direct impact on 
the course of the disease, as MCP is a resident membrane 
protein, not a circulating plasma factor. Nevertheless, a 
potential benefit of PE during relapses, to clear up other 
triggers of endothelial dysfunction, remains possible. To 
date, published data indicate that 70–80% of patients 
with a mutation in the gene encoding MCP undergo re-
mission from acute episodes, whether or not they have 
been treated with plasma therapy  [22] . PE should be con-
sidered as first-line treatment for patients with aHUS as-
sociated with anti-CFH antibodies. Steroids and various 
immunosuppressive treatments, including rituximab, all 
tried empirically, have been administered to prevent pro-
duction of antibodies after PE cessation  [49, 50, 66] but 
are unhelpful interventions used routinely.
 Although it was recently established that the coagula-
tion pathways themselves activate complement  [67] , rou-
tine use of anticoagulation is not recommended. How-
ever, low-molecular-weight heparin at prophylactic dos-
ages and low-dose aspirin are recommended after 
combined liver and kidney transplantation (see below).
 Transplantation 
 Renal transplantation for patients with aHUS cannot 
be considered without careful preliminary appraisal of 
the risk of graft loss as a result of disease recurrence. Ge-
notyping the complement regulatory and activating genes 
now allows a more precise approach to evaluating the 
posttransplant risk of recurrence in aHUS patients. The 
risk of disease recurrence after renal transplantation in 
patients with aHUS has been reviewed  [68] .
Table 3. Up-to-date recommendations for the investigation and 
therapy of patients with aHUS
Investigation
Nondiarrheal or aHUS is a clinically defined form of TMA char-
acterized by predominant renal involvement and the absence of 
Stx-producing bacteria as a triggering factor often has relapses and 
a poorer outcome
Determination of complement C3, C4, CFH, CFI and CFB levels, 
expression of MCP and screening for anti-CFH antibodies are in-
dicated for all patients with aHUS; normal C3 level does not ex-
clude dysfunction of complement regulation (i.e. regulation of the 
alternative pathway)
Genotyping of genes encoding the complement regulators CFH, 
CFI and MCP and activators C3 and CFB is indicated for all pa-
tients with aHUS, even if plasma levels are normal
The identified gene mutation has to be regarded as a risk factor for 
aHUS, not as the direct cause. Penetrance of the disease is 50% in 
patients with a mutation in complement. Therefore, the risk of de-
veloping aHUS is difficult to predict in a family member present-
ing the mutation. Unaffected family members presenting with a 
mutation, however, should be monitored during periods of in-
creased risk (such as pregnancy and infections) 
A postdiarrheal onset of the disease does not exclude aHUS 
Therapy
PE (with FFP) should be started as early as possible. Benefit is ex-
pected mainly in CFH-mutated patients and in patients with anti-
CFH antibodies; benefit is also likely in all other groups, except the 
MCP mutated subgroup, where spontaneous remission generally 
occurs 
The risk of graft loss due to recurrence is high in patients with CFH 
and CFI gene mutations, while it is very low in patients with MCP 
gene mutations 
Living donor transplantation is relatively contraindicated because 
of the risk of graft loss due to recurrence and in family members 
also because of the risk that donors themselves might have aHUS 
after donation as a result of unknown genetic factors shared with 
the recipient
Kidney transplantation under pre-, intra-, and postoperative in-
tensive plasma therapy may be successful in some patients
Combined liver and kidney transplantation under pre- and intra-
operative plasma therapy, and postoperative anticoagulation has 
been successful in a few patients with CFH gene mutations; this 
option will now have to be considered on an individual basis also 
for patients with CFI gene mutations, but assessment of the risk/
benefit ratio requires careful and individual attention
Hope for the future relies on therapies which could prevent ESRD, 
such as CFH concentrate or anti-C5 monoclonal antibodies
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 Posttransplant Risk of Recurrence and Possible 
Prevention 
 While the risk of posttransplant recurrence is less 
than 1% in Stx-associated HUS patients  [69] , it is approx-
imately 80% in CFH or CFI gene-mutated patients and 
most of them lost their graft within 1 year after recur-
rence  [68] . As nonmutated MCP is acquired by the graft, 
no posttransplant recurrence is expected to occur in 
MCP gene-mutated patients and these patients can rea-
sonably go to transplantation. Nevertheless, of the 10 
MCP gene-mutated patients transplanted and published 
in the literature, 2 had posttransplant recurrence. One of 
them most probably had a second mutation in another 
regulator of the complement system  [70] . In the other 
patient, endothelial microchimerism was suggested by 
the colonization of the graft endothelia by the recipient’s 
MCP-deficient cells  [71] . The risk of recurrence in CFB 
or C3 gene-mutated patients is not well documented, as 
to date, there have been only a small number of patients 
with these genetic defects published in the literature. The 
risk of recurrence after transplantation in patients with 
no mutation is about 30%  [68] . These findings under-
score the clinical heterogeneity of outcome after renal 
transplantation in patients with aHUS and highlight the 
imperative for comprehensive complement analysis and 
genetic testing prior to renal transplantation in all pa-
tients with aHUS.
 Avoidance of calcineurin inhibitors for immunosup-
pression does not lower the incidence of aHUS recur-
rence after transplantation. As frequency and duration 
of plasma therapy, therapeutic modalities (PE or FFP in-
fusions) or volume of FFP infused or exchanged to pre-
vent recurrence of aHUS after transplantation were 
highly variable in historical series, the effect of treatment 
is difficult to ascertain. Nevertheless, the efficiency of 
intensive prophylactic plasma therapy started before 
transplantation seems to have been demonstrated in the 
past  [65] and is consistent with our own experience 
 [72] .
 Taken into account the risk of graft loss due to recur-
rence, living donor transplantation is relatively contrain-
dicated, but has to be considered individually and, in ad-
dition, in family members, the risk that donors them-
selves might have aHUS after donation, due to unknown 
genetic factors shared with the recipient, has to be con-
sidered  [73] .
 Combined Liver and Kidney Transplantation 
 Both CFH and CFI are produced mainly in the liver, 
and successful liver transplantation would theoretically 
restore normal complement regulation and prevent dis-
ease recurrence. The first 3 combined liver-kidney and 
auxiliary liver transplantations in children with CFH 
deficiency were disappointing, as 1 child had severe 
neurologic sequelae and died 3 years later, 1 child died 
short after transplantation from primary liver nonfunc-
tion and the child with the auxiliary liver transplanta-
tion developed posttransplantation lymphoproliferative 
disease and bacterial sepsis and died 11 months after 
auxiliary liver transplantation  [74] . In the 1 child who 
died from primary liver nonfunction, autopsy of the liv-
er showed diffuse thrombotic and ischemic lesions, 
most likely due to the thrombogenic effect of comple-
ment activation products deposited on the microvascu-
lature of the liver after transplantation. Taking into ac-
count that liver transplantation might trigger intense 
local complement activation, these initial experiences 
suggested that liver transplantation should be per-
formed under intensive pre- and perioperative plasma 
therapy to correct complement dysregulation. The first 
successful combined liver and kidney transplantation (a 
5-year-old male child with CFH deficiency, who had lost 
a first graft due to recurrence at the age of 2) was re-
ported in 2006 by Saland et al.  [74] . The pivotal modifi-
cation of the transplant procedure was to exchange plas-
ma before transplantation with further plasma supple-
mentation during surgery. This both increased the 
bioavailability of functional CFH during the critical pe-
riod needed for the liver graft to recover synthetic func-
tions and, at the same time, removed the endogenous 
mutant CFH. In addition, posttransplant anticoagula-
tion with low-molecular-weight heparin at prophylactic 
dosages and low-dose aspirin was used in each of the 
successful procedures  [74] . To date, 3 further successful 
combined kidney and liver transplantations in patients 
with CFH gene mutations (2 children and 1 adolescent 
patient) have been done  [74] . After the success of the ini-
tial combined transplantations, a consensus conference 
on kidney and liver transplantation in aHUS was held 
in December 2007 and the recommendations have re-
cently been published. In summary, these authors pro-
pose combined liver and kidney transplantation as the 
preferred option for aHUS patients with ESRD and mu-
tations in the CFH gene and possibly also for patients 
with mutations in the CFI gene  [74] . However, risks as-
sociated with this not yet established procedure of com-
bined liver-kidney transplantation still remain, and as-
sessment of the risk/benefit ratio requires careful and 
individual attention.
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 Way Forward – Future Therapeutic Options 
 It seems likely that specific treatments will be needed 
once the cause of aHUS has been identified. In patients 
with genetic CFH abnormalities it seems obvious to give 
normal CFH. A human plasma-derived CFH concentrate 
has been developed commercially with that intention, 
and it received the European orphan drug designation in 
January 2007. Substitution with CFH concentrate is a 
therapeutic option for patients with quantitative and 
functional CFH deficiency but it will have to be taken 
into account that such commercial concentrates have a 
short half-life. The same logic applies to aHUS associated 
with CFI gene mutations but a CFI concentrate is still not 
available.
 Concerning the damage mediated by unregulated 
complement activation, monoclonal humanized anti-
bodies against the key activating components of the fi-
nal complement pathway such as C5 are a promising 
therapeutic option for patients with aHUS. Prevention 
of C5 activation has been shown to ameliorate sponta-
neous and experimental glomerulonephritis in CFH-
deficient mice  [75] . The long-term efficacy and toler-
ance of the anti-C5 monoclonal antibody eculizumab 
have been demonstrated in large cohorts of patients 
with paroxysmal nocturnal hemoglobinuria, a well-in-
vestigated complement disease  [76–78] . To date, 2 cases 
of aHUS who were unresponsive to PE therapy have 
been published in the literature, presenting with hema-
tologic and renal improvement after administration of 
eculizumab: an 18-month-old boy with congenital re-
lapsing aHUS  [79] and a 37-year-old woman with aHUS 
associated with a CFH and CFHR1 gene mutation and 
recurrence of aHUS 6 weeks after the second kidney 
transplantation  [80] . These data show the positive effect 
of complement inhibition on the course of aHUS and 
provide impetus for the evaluation of eculizumab in 
controlled clinical trials.
 Summary 
 aHUS is a disorder of alternative pathway dysregula-
tion. A growing list of ‘loss-of-function’ mutations and 
polymorphisms in genes encoding regulatory proteins 
has been demonstrated to predispose to aHUS. Addition-
ally, ‘gain-of-function’ mutations in complement activa-
tion genes have now been associated with aHUS. Recent 
advances in understanding the pathogenesis of aHUS 
have clinical significance in predicting renal recovery 
and transplant outcome. It is important to analyze the 
complement profile of patients with aHUS, including ge-
netic screening as well. This may also provide opportuni-
ties for more specific treatments in the near future, as 
complement inhibition could represent a therapeutic tar-
get in patients with aHUS.
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 The minireview by Hirt-Minkowski and colleagues 
from Basel updates the reader on recent advances in the 
understanding of the genetics, pathophysiology and 
management of atypical hemolytic uremic syndrome. It 
sheds light on the rapidly expanding number of genetic 
mutations involving the complement system: comple-
ment factor H (CFH), membrane cofactor protein, com-
plement factor I, complement factor B and C3 as well as 
thrombomodulin. Complement component activation, 
dysfunction or inactivation by autoantibodies seems to 
play a predominant role in the pathogenesis of this condi-
tion. The review also examines the rationale behind cur-
rent and established therapies such as plasma exchange 
with fresh frozen plasma or plasma products such as Oc-
taplas, namely the removal of dysfunctional complement 
components and/or autoantibodies and replacement with 
normal plasma components. It also explores new thera-
pies aimed at modulating the complement system includ-
ing anti-C5 monoclonal antibodies (eculizumab) and a 
human plasma-derived CFH concentrate. This is a rare 
disease where nephrology has made huge strides in the 
last decade. It exemplifies a condition where a better un-
derstanding of genetics sheds light on pathophysiology 
and leads to new therapies.
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